过早衰老和神经病态行为是由急性低剂量暴露于沙林替代品引起的
Alexandre Champault1, Sarah Leterrier2, Rosalie Bel3
1Department of Toxicology and Chemical Risks, Armed Forces Biomedical Research Institute, Bretigny sur Orge, France; Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), CEA, CNRS, Inserm, Université Paris-Saclay, Service Hospitalier Frédéric Joliot, Orsay, France.
Toxicology
|October 31, 2025
概括
暴露于有机 (OP) 化合物,即使在亚致死的剂量,也会导致小鼠的过早衰老和长期的感觉运动缺陷. 这凸显了需要识别微妙的中毒迹象,以便及早介入的必要性.
科学领域:
- 神经科学是一个神经科学.
- 毒理学 毒理学 毒理学
- 衰老研究研究 衰老研究
背景情况:
- 有机 (OP) 化合物可以引起急性胆固醇毒性毒性病.
- 延迟的神经效应,如肌肉衰弱和感官丧失,尚未得到充分的探索.
- 这些症状与老年人的症状相似.
研究的目的:
- 调查杀性OP暴露的长期传感运动效应.
- 使用暴露于沙林替代品 (NIMP) 的小鼠模型.
- 在六个月内评估神经,代谢和细胞变化.
主要方法:
- 给小鼠施用0.5 LD50剂量的4-尼托菲尼尔异甲基酸盐 (NIMP).
- 进行了运动和感官功能的行为测试.
- 测量了乙胆酶活性,进行了PET和微CT扫描,并使用了Luminex测定.
主要成果:
- 暴露于NIMP会引起轻度中毒,但不会影响体重.
- 小鼠表现出持续的肌肉衰弱和机械灵敏度增加.
- 长期影响包括抑制皮质乙胆酶,改变大脑代谢,减少骨密度和增加衰老生物标志物.
结论:
- 在小鼠中,次致命的NIMP暴露会诱导过早衰老的表型.
- 这导致持续的感觉运动障碍和神经代谢障碍.
- 即使在无症状的情况下,早期识别OP中毒特征至关重要.
相关概念视频
Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...


